Review of cancer treatment with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Review of cancer treatment with immune checkpoint inhibitors

Published:2017-11-02 Issue:3-4 Volume:130 Page:85-91
ISSN:0043-5325
Container-title:Wiener klinische Wochenschrift
language:en
Short-container-title:Wien Klin Wochenschr

Author:

Thallinger Christiane^ORCID,Füreder Thorsten,Preusser Matthias,Heller Gerwin,Müllauer Leonhard,Höller Christoph,Prosch Helmut,Frank Natalija,Swierzewski Rafal,Berger Walter,Jäger Ulrich,Zielinski Christoph

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1007/s00508-017-1285-9/fulltext.html

Reference62 articles.

1. Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 2017;10:1487–502.

2. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.

3. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T‑cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73(23):6900–12.

4. Kumar R, Yu F, Zhen YH, Li B, Wang J, Yang Y, Ge HX, Hu PS, Xiu J. PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells. Onco Targets Ther. 2017;10:3453–65.

5. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The advancement of molybdenum disulfide quantum dots nanoparticles as nanocarrier for drug delivery systems: Cutting-edge in dual therapeutic roles;Journal of Molecular Structure;2024-12

2. Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study;PLOS ONE;2024-07-31

3. Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study;Cancer Immunology, Immunotherapy;2024-06-08

4. An insight into the dual role of MoS2-based nanocarriers in anticancer drug delivery and therapy;Acta Biomaterialia;2024-04

5. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study;British Journal of Dermatology;2024-02-15